How can we train the immune system to fight cancer?

The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient's own immune cells on-site to kill cancer cells. This revolutionary immunomaterial technology was tested in a successful Phase I clinical trial and is currently licensed by Novartis as an immunotherapy to treat specific tumor types. For more information, please visit: https://wyss.harvard.edu/technology/i... Credit: Wyss Institute at Harvard University